



HAL
open science

Classifying Idiopathic Rapid Eye Movement Sleep Behavior Disorder, Controls, and Mild Parkinson's Disease Using Gait Parameters

Valérie Cochen de Cock, Dobromir Dotov, Sandy Lacombe, Marie Christine Picot, Florence Galtier, Valérie Driss, Castelnovo Giovanni, Christian Geny, Beatriz Abril, Loic Damm, et al.

► **To cite this version:**

Valérie Cochen de Cock, Dobromir Dotov, Sandy Lacombe, Marie Christine Picot, Florence Galtier, et al.. Classifying Idiopathic Rapid Eye Movement Sleep Behavior Disorder, Controls, and Mild Parkinson's Disease Using Gait Parameters. *Movement Disorders*, 2022, 37 (4), pp.842-846. 10.1002/mds.28894 . hal-03559632

HAL Id: hal-03559632

<https://imt-mines-ales.hal.science/hal-03559632v1>

Submitted on 8 Jun 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Classifying Idiopathic Rapid Eye Movement Sleep Behavior Disorder, Controls, and Mild Parkinson's Disease Using Gait Parameters

Valérie Cochen De Cock, MD, PhD,^{1,2*}
Dobromir Dotov, PhD,² Sandy Lacombe, Msc,³
Marie Christine Picot, MD, PhD,^{4,5} Florence Galtier, MD,⁵
Valérie Driss, Msc,⁵ Castelnovo Giovanni, MD,⁶
Christian Geny, MD,^{2,7} Beatriz Abril, MD,⁸
Loïc Damm, PhD,^{2,3} and Stefan Janaqi, PhD^{2*}

¹Sleep and Neurology Department, Beau Soleil Clinic, Montpellier, France ²EuroMov Digital Health in Motion, University of Montpellier IMT Mines Ales, Montpellier, France ³Department of Epidemiology and Biostatistics, Beau Soleil Clinic, Montpellier, France ⁴Clinical Research & Epidemiology Unit, Medical Information Department, CHU Montpellier, University of Montpellier, Montpellier, France

⁵Clinical Investigation Centre 1411, University Hospital of Montpellier & Inserm, Montpellier, France ⁶Département of Neurology, University Hospital of Nîmes, France ⁷Department of Neurology, University Hospital of Montpellier, Montpellier, France

⁸Sleep Department, University Hospital of Nîmes, Nîmes, France

ABSTRACT: Background: Subtle gait changes associated with idiopathic rapid eye movement sleep behavior disorder (iRBD) could allow early detection of subjects with future synucleinopathies.

Objective: The aim of this study was to create a multiclass model, using statistical learning from probability distribution of gait parameters, to distinguish between patients with iRBD, healthy control subjects (HCs), and patients with Parkinson's disease (PD).

Methods: Gait parameters were collected in 21 participants with iRBD, 21 with PD, and 21 HCs, matched for age, sex, and education level. Lasso sparse linear regression explored gait features able to classify the three groups.

Results: The final model classified iRBD from HCs and from patients with PD equally well, with 95% accuracy, 100% sensitivity, and 90% specificity.

Conclusions: Gait parameters and a pretrained statistical model can robustly distinguish participants with iRBD from HCs and patients with PD. This could be used to screen subjects with future synucleinopathies in the general population and to identify a conversion threshold to PD.

Key Words: idiopathic REM sleep behavior disorder; iRBD; gait parameters; Parkinson's disease; machine learning classification; conversion

Robust prodromal clinical biomarkers of Parkinson's disease (PD) need to be identified to allow early interventions when dopaminergic neuronal loss is not too advanced.^{1,2} Idiopathic rapid eye movement sleep behavior disorder (iRBD)³ seems to be the strongest predictor for synucleinopathies.⁴⁻⁶ It is not always present in PD, especially at the prodromal stage, but it can be used to identify other biomarkers. iRBD is associated with subtle gait abnormalities, measured in terms of clinical motor assessments.⁷⁻¹⁰ For individualized classification, however, neither of these variables is sufficient alone, although a multiclass predictive model for iRBD, HC, and PD that uses machine learning^{11,12} to combine a range of gait characteristics variability could be very useful.

Subjects and Methods

Participants

Twenty-one patients with iRBD (4 females), 21 patients with PD, and 21 healthy control subjects (HCs), matched for age, sex, and educational level, were recruited for the study. Participants with iRBD were recruited at the sleep disorders department of the Beau Soleil Clinic in Montpellier and the Regional University Hospital of Nîmes (France). iRBD was confirmed after one-night polysomnographic recording according to the criteria of the International Classification of Sleep Disorders.¹³ None of the iRBD participants had drug-induced RBD. All of them had a neurological evaluation to rule out the presence of other neurological or neurodegenerative diseases.

Patients with PD were recruited in the Department of Neurology of the Beau Soleil Clinic and the Regional University Hospital of Montpellier (France). Diagnosis

*Correspondence to: Dr. Valérie Cochen De Cock or Dr. Stefan Janaqi, Pôle Sommeil et Neurologie, Clinique Beau Soleil, 119 avenue de Lodève, 34070 Montpellier, France or EuroMov Digital Health in Motion, University of Montpellier, IMT Mines Ales, Montpellier, France; E-mail: valerie.cochen@gmail.com (V.C.D.C.) or E-mail: stefan.janaqi@mines-ales.fr (S.J.)

Relevant conflicts of interest/financial disclosures: Nothing to report.

was established according to the Queen Square Brain Bank criteria.¹⁴ Participants were kept on their usual medications during the evaluation. Twelve (57%) of 21 patients with PD complained about ongoing RBD.¹⁵ They did not have polysomnography to confirm RBD and were considered as probable RBD.

HCs were community-dwelling adults recruited via a volunteers' database maintained by the Clinical Investigation Centre of the Montpellier University Hospital.

The study was approved by the National Ethics Committee (CPP Sud Méditerranée III, Nîmes, France; ID-RCB: 2013-A01265-40). All participants gave written informed consent to participate.

Procedure

Clinical and Psychological Evaluation

Demographic characteristics and medical history were collected in a preliminary interview. Motor severity of the disease was evaluated using the Hoehn and Yahr scale¹⁶ and Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III¹⁷ in "on" condition. The levodopa equivalent daily dose was calculated.¹⁸ Nonmotor and motor experiences of daily living were evaluated using MDS-UPDRS Parts I and II, respectively¹⁷; dysautonomia using assessment of autonomic dysfunction in PD (SCOPA-AUT)¹⁹; global cognitive functioning using Montreal Cognitive Assessment²⁰; and anxiety and depressive symptoms using the Hospital Anxiety and Depression scale.²¹

Gait

Gait was recorded in a 20-m-long, 5-m-wide corridor. Subjects were asked to walk straight and turn around at each end of the corridor. There were three conditions: single-task walking (*ST*), dual-task walking with counting plus one (D_{+1}), and counting minus three (D_{-3}). The instruction to switch task was given each round in the middle of the corridor. Patients completed 13 rounds. Task was changed pseudorandomly. Every dual-task round was separated by a single-task round.

Six inertial measurement units (128 Hz; MobilityLab; APDM Inc., Portland, OR, USA) were strapped to wrists, ankles, and on the trunk in the sternal and lumbar position. Fifty-nine gait parameters were extracted: stride length and velocity; cadence; gait cycle time; double support; swing and stance; ranges of motion; angular velocities of legs, arms, and trunk; and asymmetries of the stride, swing, stance, leg, and arm movements.

Technical difficulties prevented recording in three subjects (PD01, HC07, and HC12).

Olfaction

Olfactory function was evaluated using standardized Sniffin' Sticks.²²

Statistical Analyses

Group Comparisons

Independent-sample *t* test or Mann-Whitney tests were used for continuous variables, depending on the normality of the distribution, and χ^2 tests or Fisher's exact tests for categorical ones. Significance level was set at $P < 0.05$.

Classification

A classification model aggregating multiple gait features was trained to predict true health status, $y = HC, iRBD, PD$. We split the dataset into trained (75%) and test set (25%). The model learned only with the trained set, was then tested with the unseen test set, separately for each task, *ST*, D_{+1} , and D_{-3} , as well as combining the data across these tasks.

We used the probability distribution obtained for each gait measure from the repeated observations over walking rounds. Then the values of this probability in each bin were used as classification features. For a number of bins ($n = 100$) this resulted in an initial set of 5900 candidate features (100 bins per 59 measures).

Next, a predictive model was obtained with the well-known and easily interpretable Lasso linear regression.²³ This is a sparse learning technique that fits the true status y with the function $Y \approx f(x, b, w) = b + w_1x_1 + w_2x_2 + \dots$, consisting of an intercept b , features x , and weights w . The weights are used to automatically select a small subset from the highly redundant feature set through a penalizing "sifting" procedure that sets most weights to zero. The linear regression returns a continuous classification variable Y that is cast into the pathology class by thresholding: $\hat{y} = HC$ if $Y < 1.5$, $\hat{y} = iRBD$ if $1.5 \leq Y < 2.5$, and $\hat{y} = PD$ if $Y \geq 2.5$ (see Fig. 1).

Correlations with Early Markers of PD

Finally, we addressed whether the learned model agreed with known early markers of PD. To this end, we took the Pearson correlations between the aggregate classification variable Y from the model and clinical measures.

Results

Clinical Characteristics

Demographic and clinical characteristics for participants with *iRBD*, participants with PD, and HCs are presented in Table 1. Patients with PD had a mild disease with a mean Hoehn and Yahr at 1.52 ± 0.75 . Disease duration was 4.24 ± 2.77 years, and age at onset




FIG. 1. Lasso classification. (A) Final model discriminating idiopathic rapid eye movement sleep behavior disorders (iRBDs) from healthy control subjects (HCs) and from patients with Parkinson's disease (PD) equally well with 95% accuracy, 100% sensitivity, and 90% specificity in single task ($P < 0.0001$). (B) Contribution of the different discriminating variables. Range and speed of motion are the main contributors of the model.

was 65.52 ± 7.72 years. Levodopa equivalent daily dose was 258.7 ± 214.7 mg. RBD duration was not different between patients with iRBD and patients with PD and probable RBD (11.70 ± 11.85 vs. 10.10 ± 12.22 ; $P = 0.8$).

In participants with iRBD, subtle motor manifestations were common, with more tremor on motor examination than HCs. They had impaired olfaction. They tended to report more dysautonomia and more depressive symptoms than HCs (Table 1). As expected, participants with iRBD had fewer motor and nonmotor, depressive, and dysautonomic symptoms than patients with PD. They did not differ for global cognition, depressive symptoms, and olfaction dysfunction (Table 1).

Classification

The accuracy of classification of iRBD from HCs and from patients with PD, as evaluated on the test set,

were very high, 95% and 98%, respectively. Sensitivity of classification of iRBD from HCs and patients with PD was 100% for both, and specificity was, respectively, 91% and 95% (Fig. 1A). The same classification performance was obtained in each of the tasks (ST , D_{+1} , D_{-3}) and the combination of all three.

The Lasso method retained 34 features of 5900. For the single-task condition, these 34 features belonged to 22 gait original measures that come from six clinical signs. The contribution of these signs is reported in Fig. 1B.

We observed strong correlations (defined as coefficient of correlation $> |0.6|$) between the classification variable Y and most of the olfaction measures (threshold -0.73 , $P < 0.001$; identification -0.69 , $P < 0.001$; sum score -0.70 , $P < 0.001$). We noted weak but significant correlations with olfaction discrimination (-0.41 , $P < 0.05$), tremor (0.42 , $P < 0.05$), and non-motor aspects of daily living (0.35 , $P < 0.05$).

TABLE 1 . Clinical characteristics of healthy control subjects, subjects with idiopathic rapid eye movement sleep behavior disorder, and Parkinson's disease

Characteristics	HCs (n = 21)	iRBD (n = 21)	PD (n = 21)	P	
				IRBD vs. HC	IRBD vs. PD
Age (y)	69.8 ± 6.8	68.7 ± 6.9	69.8 ± 7.9	0.6	0.6
Sex (% of women)	19	19	19	1	1
Body mass index (kg/m ²)	25.8 ± 3.2	26.1 ± 3.7	25.1 ± 3.7	0.6	0.6
National adult reading test	110.2 ± 5.0	108.7 ± 9.1	111.6 ± 5.5	0.7	0.4
Education (y)	12.8 ± 4.0	12.5 ± 4.1	13.5 ± 4.1	0.8	0.3
Motor aspects					
Motor aspects of experiences of daily living (MDS-UPDRS Part II/52)	1.1 ± 1.9	0.5 ± 0.9	7.9 ± 6.4	0.3	<0.0001
Motor disability (MDS-UPDRS Part III/132) when treated for PD	3.8 ± 2.6	5.3 ± 4.5	17.2 ± 9.2	0.3	<0.0001
Axial signs	0.6 ± 0.7	1.0 ± 0.9	2.2 ± 1.4	0.2	<0.01
Tremor	0.0 ± 0.0	0.7 ± 0.9	2.8 ± 2.6	<0.01	<0.001
Falls self-efficacy scale score	7.4 ± 0.9	7.5 ± 1.0	10.2 ± 4.4	0.3	0.01
Nonmotor aspects of daily living					
MDS-UPDRS Part I/52	4.2 ± 3.9	6.8 ± 4.9	12.2 ± 5.0	0.06	<0.0001
Global cognitive function (MoCA)	27.2 ± 2.1	26.2 ± 3.3	26.6 ± 2.4	0.7	0.9
Hospital anxiety depression scale: anxiety	4.4 ± 3.3	5.6 ± 3.6	6.8 ± 3.5	0.3	0.1
Hospital anxiety depression scale: depression	1.9 ± 2.6	3.1 ± 2.4	4.9 ± 3.5	0.06	0.03
Dysautonomia (SCOPA-AUT)	5.4 ± 2.9	7.7 ± 5.2	13.6 ± 5.7	0.07	<0.001
Olfaction					
Threshold	7.4 ± 1.7	3.2 ± 2.1	3.7 ± 1.5	<0.0001	0.6
Discrimination	11.4 ± 2.0	8.6 ± 3.2	7.8 ± 3.4	0.001	0.4
Identification	13.1 ± 1.6.2	7.6 ± 3	6.8 ± 3.6	<0.0001	0.3
Sum score	31.9 ± 3.4	19.4 ± 7.1	18.2 ± 7.0	<0.0001	0.5

Data are shown as mean ± SD. Boldface values reached statistical significance of $P < 0.05$.

HC, healthy control subject; iRBD, idiopathic rapid eye movement sleep behavior disorder; PD, Parkinson's disease; MoCA, Montreal Cognitive Assessment; MDS-UPDRS, Movement Disorder Society-Unified Parkinson's Disease Rating Scale; SCOPA-AUT, assessment of autonomic dysfunction in Parkinson's disease.

Discussion

We have demonstrated that using statistical learning methods to explore gait measures, one can identify robust discriminating variables to screen HCs from patients with high risk to develop synucleinopathies (mostly PD or dementia with Lewy bodies), such as patients with iRBD. Thanks to a noninvasive, quick-to-perform, and cheap gait detection method, we can screen future synucleinopathies from HCs. We observed that using a dual task did not improve our accuracy, making the testing duration even faster. Our discriminating variables are strongly correlated with olfaction dysfunction, which is another marker associated with high risk for future synucleinopathies. Our method, which also allows discriminating patients with iRBD

and PD, could help address the challenging task of distinguishing early PD and advanced iRBD.

Subtle gait disorders have already been identified as risk factors for future PD.⁷⁻¹⁰ However, these differences were identified at the group level but never did authorize a screening of a future PD population. Recent studies examined the role of gait in conversion to PD.^{24,25} Our approach confirms their results but also differs from theirs because it quantifies the role of gait features into a predicting statistical model.

A large set of gait parameters was collected and analyzed, as well as their variability within time. This last subset of variables contributed to the sensitivity of group screening. Based on the variability of the distribution of our data, we successfully screened iRBD from HCs and patients with PD with a sensitivity of 100%

and a specificity of 90% with very high levels of significance.

Our results confirm that gait disorders occur early in the development of synucleinopathies. The gait parameters that classified our groups were mostly amplitude and speed of movement. These abnormalities are the classical clinical signs observed in a full-blown parkinsonian syndrome but are so subtle in iRBD that they usually remain undetectable for clinicians. It is their variation in time that allowed us to screen subjects with iRBD, with high risk to develop synucleinopathies, compared with HCs and patients with PD. Gait parameters of patients with iRBD appear to exhibit parkinsonian signs, but in a discreet, discontinuous, and variable way. Cadence and phase difference were also involved, suggesting a rhythmicity dysfunction. This is in line with our recent results suggesting rhythm disturbances as a potential early marker of PD.²⁶

The main limitations of our study are the low sample size and the cross-sectional rather than longitudinal design of the study, which calls for further investigation in a larger population and in a longitudinal way. We could also have used more challenging dual tasks.

In conclusion, our work supports the idea that subtle and time-varying gait disorders appear early in PD or more broadly in synucleinopathies even at the preclinical phase of the disease. Our results encourage considering the use of new technologies to measure gait parameters and their time variability as screening tools in studies targeting disease-modifying agents. This approach is also a promising tool for the prediction of disease progression at a prodromal stage.

Acknowledgments: This research was supported by GCS MERRI MONTPELLIER-NIMES 2013. We acknowledge all the subjects who participated in the study.

Data Availability Statement

Data are available on request

References

1. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. *Brain* 1991;114:2283–2301.
2. de la Fuente-Fernandez R, Schulzer M, Kuramoto L, et al. Age-specific progression of nigrostriatal dysfunction in Parkinson's disease. *Ann Neurol* 2011;69:803–810.
3. Schenck CH, Bundlie SR, Ettinger MG, Mahowald MW. Chronic behavioral disorders of human REM sleep: a new category of parasomnia. *Sleep* 1986;9:293–308.
4. Postuma RB, Gagnon JF, Vendette M, et al. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. *Neurology* 2009;72:1296–1300.
5. Iranzo A, Molinuevo JL, Santamaría J, et al. Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. *Lancet Neurol* 2006;5:572–577.
6. Postuma RB, Iranzo A, Hu M, et al. Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. *Brain* 2019;142:744–759.
7. Postuma R, Lang A, Gagnon J, Pelletier A, Montplaisir J. How does parkinsonism start? Prodromal parkinsonism motor changes in idiopathic REM sleep behaviour disorder. *Brain* 2012;135:1860–1870.
8. McDade E, Boot B, Christianson T, et al. Subtle gait changes in patients with REM behavior disorder. *Mov Disord* 2013;28:1847–1853.
9. Ehgoetz Martens K, Matar E, Hall J, et al. Subtle gait and balance impairments occur in idiopathic rapid eye movement sleep behavior disorder. *Mov Disord* 2019;34:1374–1380.
10. del Din S, Yarnalla A, Barberc T, et al. Continuous real-world gait monitoring in idiopathic REM sleep behavior disorder. *J Parkinsons Dis* 2020;10:283–299.
11. Stephansen JB, Olesen AN, Olsen M, et al. Neural network analysis of sleep stages enables efficient diagnosis of narcolepsy. *Nat Commun* 2018;9:5229.
12. Vallinai AA-A, Ranti D, Oermann EK. Deep learning and neurology: a systematic review. *Neurol Ther* 2019;8:351–355.
13. American Academy of Sleep Medicine. International Classification of Sleep Disorders. 3rd ed. Westchester, IL: American Academy of Sleep Medicine; 2014.
14. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. *J Neurol Neurosurg Psychiatry* 1992;55:181–184.
15. Postuma RB, Arnulf I, Hogl B, et al. A single-question screen for rapid eye movement sleep behavior disorder: a multicenter validation study. *Mov Disord* 2012;27:913–916.
16. Hoehn M, Yahr MD. Parkinsonism: onset, progression and mortality. *Neurology* 1967;17:427–442.
17. Martinez-Martin P, Rodriguez-Blazquez C, Alvarez-Sanchez M, et al. Expanded and independent validation of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS). *J Neurol* 2013;260:228–236.
18. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. *Mov Disord* 2010;25:2649–2653.
19. Visser M, Marinus J, Stiggelbout AM, van Hilten JJ. Assessment of autonomic dysfunction in Parkinson's disease: the SCOPA-AUT. *Mov Disord* 2004;19:1306–1312.
20. Dalrymple-Alford JC, MacAskill MR, Nakas CT, et al. The MoCA: well-suited screen for cognitive impairment in Parkinson disease. *Neurology* 2010;75:1717–1725.
21. Marinus J, Leentjens AFG, Visser M, Stiggelbout AM, van Hilten JJ. Evaluation of the hospital anxiety and depression scale in patients with Parkinson's disease. *Clin Neuropharmacol* 2002;25:318–324.
22. Hummel T, Sekinger B, Wolf SR, Pauli E, Kobal G. Sniffing sticks: olfactory performance assessed by the combined testing of odour identification, odour discrimination and olfactory threshold. *Chem Senses* 1997;22:39–52.
23. Tibshirani R. Regression shrinkage and selection via the lasso. *J R Stat Soc B Methodol* 1996;58:267–288.
24. del Din S, Elshehabi M, Galna B, et al. Gait analysis with wearables predicts conversion to Parkinson disease. *Ann Neurol* 2019;86:357–367.
25. Pistacchi M, Gioulis M, Sanson F, et al. Gait analysis and clinical correlations in early Parkinson's disease. *Funct Neurol* 2017;32:28–34.
26. Cochen De Cock V, de Verbizier D, Picot MC, et al. Rhythm disturbances as a potential early marker of Parkinson's disease in idiopathic REM sleep behavior disorder. *Ann Clin Transl Neurol* 2020;7:280–287.

SGML and CITI Use Only
DO NOT PRINT

Author Roles

(1) Research Project: A. Conception, B. Organization, C. Execution;
(2) Statistical Analysis: A. Design, B. Execution, C. Review and Critique;
(3) Manuscript: A. Writing of the first draft, B. Review and Critique.
Valérie Cochen De Cock: 1A, 1B, 1C, 3A, 3B
Dobromir Dotov: 1C, 2C, 3B
Loic Damm: 2C, 3B
Sandy Lacombe: 2B, 3B
Marie Christine Picot: 1A, 1B, 2C, 3B
Florence Galtier: 1A, 1B, 1C, 2C, 3B
Valérie Driss: 1B, 1C
Castelnuovo Giovanni: 1C, 3B
Christian Geny: 1C, 3B
Beatriz Abril: 1C, 3B
Stefan Janaqi: 2A, 2B, 3A, 3B

Financial Disclosures

D.D., L.D., S.L., M.C.P., F.G., V.D., C.G., B.A., and S.J. have no financial disclosures for the last 12 months. V.C.D.C has served on a scientific advisory board for Jazz Pharma and received honoraria for speeches from Orkyn, Aguettant and LVL medical; received research support from Orkyn and Aguettant; and received travel grants from Orkyn and Aguettant.